Compare Rocket Lab USA Inc (RKLB) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rocket Lab USA Inc vs Sana Biotechnology Inc — how do they compare? Rocket Lab USA Inc trades at $63.3 (market cap $42.12B), while Sana Biotechnology Inc trades at $3.24 (market cap $1.03B). The key difference: Rocket Lab USA Inc is far larger — about 40.9× Sana Biotechnology Inc's market cap. Which is the better fit depends on your goals.
| RKLB | SANA | |
|---|---|---|
Market Cap | $42.12B | $1.03B |
Sector | Technology | Health |
52-Week High | $150.23 | $5.92 |
52-Week Low | $39.48 | $2.68 |
Enterprise Value | $39.95B | $946.04M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rocket Lab (RKLB) trades at $65.87, up 2.51% on the day, but remains in a bearish technical trend below key resistance levels. The company reported record Q2 2026 revenue of $234 million, up 62% year-over-year, yet continues to post significant net losses. Recent news highlights progress on the Neutron rocket and the pending Iridium Communications acquisition, but investor sentiment is mixed due to execution risks and delays.
The outlook hinges on successful Neutron deployment and path to profitability. Analysts see substantial upside with a $117.44 consensus target, but risks include cash burn, competitive pressure, and potential further launch delays. The stock offers high-growth potential for risk-tolerant investors betting on the space economy's expansion.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
